Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open‑label Phase 2 ALPHA3 study

Blood (2025) 146 (Supplement 1): 3730.

https://doi.org/10.1182/blood-2025-3730

Published: 2025

Journal Articles

Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations

Blood (2025) 146 (Supplement 1): 4069.

https://doi.org/10.1182/blood-2025-4069

Published: 2025

Journal Articles

Major adverse cardiovascular events after teclistamab in relapsed refractory multiple myeloma: A multicenter study from the u.s. multiple myeloma immunotherapy consortium.

Blood (2025) 146 (Supplement 1): 4066.

https://doi.org/10.1182/blood-2025-4066

Published: 2025

Journal Articles

Real-world outcomes of talquetamab in Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 4051.

https://doi.org/10.1182/blood-2025-4051

Published: 2025

Journal Articles

Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations

Yumeng Zhang, Fatima Tuz Zahra, Daniel DeAvila, Bijal Shah, Sameh Gaballa, Celeste Bello, Hayder Saeed, Abu-Sayeef Mirza, Leidy Isenalumhe, Omar Alexis Castaneda Puglianini, Aleksandr Lazaryan, Lubomir Sokol, Frederick Locke, Michael Jain, Zachary Thompson, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 2767.

https://doi.org/10.1182/blood-2025-2767

Published: 2025

Journal Articles

Real-world outcomes with elranatamab in multiple myeloma: A multi-center analysis from the United States multiple myeloma immunotherapy consortium

Blood (2025) 146 (Supplement 1): 136.

https://doi.org/10.1182/blood-2025-136

Published: 2025

Journal Articles

Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium

Ran Reshef, Alexandria Jensen, Christian Gordillo, Brett Reid, Danai Dima, Lauren Peres, Mahmoud Gaballa, Rahul Banerjee, Oren Pasvolsky, Aimaz Afrough, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Masooma Rana, Hitomi Hosoya, Lekha Mikkilineni, Vanna Hovanky, Saurabh Zanwar, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Omar Puglianini, Gabriel De Avila, Eli Zolotov, Evguenia Bhurtel, Ariel Grajales-Cruz, Utkarsh Goel, Aishwarya Sannareddy, Jeries Kort, Raffaella Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Zhuoer Xie, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Leyla Shune, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Saurabh Dahiya, Frederick Locke, David Miklos, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Yi Lin, Krina Patel, Doris Hansen, Surbhi Sidana

Blood (2025) 146 (Supplement 1): 134.

https://doi.org/10.1182/blood-2025-134

Published: 2025

Journal Articles

Real-time multimodal AI outperforms conventional scores for early risk prediction in BCMA CAR-T–Treated myeloma

Blood (2025) 146 (Supplement 1): 6140.

https://doi.org/10.1182/blood-2025-6140

Published: 2025

Journal Articles

CD83 CAR T overcome CD19 antigen loss in B cell malignancies after CD19-directed therapy

Brian Betts, Constanza Savid-Frontera, Shannon McSain, Kelly Walton, Nolan Beatty, Payal Goala, Shernan Holtan, Meredith Stone, Frederick Locke, Anne Eaton, Michael Linden, Renier Brentjens, Marco Davila

Blood (2025) 146 (Supplement 1): 4098.

https://doi.org/10.1182/blood-2025-4098

Published: 2025

Journal Articles

Impact of pre-existing psychiatric conditions on toxicity and outcomes of patients after BCMA-directed CAR-T cell therapy

Blood (2025) 146 (Supplement 1): 6371.

https://doi.org/10.1182/blood-2025-6371

Published: 2025

Journal Articles

Developing SEMA4A-directed CAR t cells to overcome low BCMA antigen density in multiple myeloma

Blood (2025) 146 (Supplement 1): 6100.

https://doi.org/10.1182/blood-2025-6100

Published: 2025

Journal Articles

Impact of pre-existing central nervous system conditions and cognitive impairments on toxicity and outcomes after BCMA-directed CAR-T cell therapy

Blood (2025) 146 (Supplement 1): 6370.

https://doi.org/10.1182/blood-2025-6370

Published: 2025

Journal Articles

Impact of autoimmune disease on outcomes after BCMA-directed CAR-T cell therapy for patients with multiple myeloma

Blood (2025) 146 (Supplement 1): 6362.

https://doi.org/10.1182/blood-2025-6362

Published: 2025

Journal Articles

Real-world outcomes of immune effector cell-associated hemophagocytic syndrome (IEC-HS) following ide-cel and cilta-cel therapy in relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 719.

https://doi.org/10.1182/blood-2025-719

Published: 2025

Journal Articles

Optimal ferritin threshold to diagnose immune effector cell-associated hemophagocytic syndrome (IEC-HS) following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 717.

https://doi.org/10.1182/blood-2025-717

Published: 2025

Journal Articles

Optimizing immunity to pneumococcus by vaccination with pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T cell immunotherapy

M Bakri Hammami, Dasom (Caroline) Lee, Lindsey Raymond, Meghan Menges, Salvatore Corallo, Julieta Abraham Miranda, Bijal Shah, Julio Chavez, Aleksandr Lazaryan, Michael Jain, Frederick Locke

Blood (2025) 146 (Supplement 1): 4166.

https://doi.org/10.1182/blood-2025-4166

Published: 2025

Journal Articles

Real-world effectiveness and safety outcomes by age, comorbidities, and frailty among relapsed or refractory (R/R) Mantle Cell Lymphoma (MCL) patients treated with brexucabtagene autoleucel (brexu-cel)

Amer Beitinjaneh, Supriya Gupta, Fateeha Furqan, John Baird, Wen-Kai Weng, Caron Jacobson, Soyoung Kim, Zhongyu Feng, Babatunde Adedokun, Jiali Yan, Qian Huang, Kenny Hu, Timothy Best, Ioana Kloos, Grace Lee, Mehdi Hamadani, Marcelo Pasquini, Frederick Locke

Blood (2025) 146 (Supplement 1): 3606.

https://doi.org/10.1182/blood-2025-3606

Published: 2025

Journal Articles

Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas

Fatima Tuz Zahra, Yumeng Zhang, Sameh Gaballa, Celeste Bello, Samuel Reynolds, Leidy Isenalumhe, Omar Alexis Castaneda Puglianini, Hayder Saeed, Aleksandr Lazaryan, Abu-Sayeef Mirza, Lubomir Sokol, Bijal Shah, Frederick Locke, Michael Jain, Javier Pinilla-Ibarz, Julio Chavez

Blood (2025) 146 (Supplement 1): 4555.

https://doi.org/10.1182/blood-2025-4555

Published: 2025

Journal Articles

Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study

Blood (2025) 146 (Supplement 1): 4537.

https://doi.org/10.1182/blood-2025-4537

Published: 2025

Journal Articles

Identifying candidates for outpatient administration of ciltacabtagene autoleucel (Cilta-cel) in relapsed-refractory multiple myeloma (RRMM)

Danai Dima, Lauren Peres, Leyla Shune, Christelle Leitzinger, Brett Reid, Andrew Portuguese, Raffaella Cassano Cassano, Rahul Banerjee, Nilesh Kalariya, Oren Pasvolsky, Mahmoud Gaballa, Zachary Hunzeker, Christen Dillard, Hitomi Hosoya, Lekha Mikkilineni, Rebecca Gonzalez, Ariel Grajales-Cruz, Omar Alexis Castaneda Puglianini, Taiga Nishihori, Charlotte Wagner, Christopher Cahoon, Douglas Sborov, Evguenia Bhurtel, Jeries Kort, Marcus Geer, Sneha Purvey, Christopher Ferreri, Cindy Varga, Shebli Atrash, Peter Voorhees, Utkarsh Goel, Jack Khouri, Shahzad Raza, Faiz Anwer, Aimaz Afrough, Aishwarya Sannareddy, Larry Anderson, Hamza Hassan, Megan Herr, Ran Reshef, Christian Gordillo, Eli Zolotov, Noa Biran, James Davis, Kimberly Green, Saurabh Zanwar, Yi Lin, Luciano Costa, Susan Bal, Shonali Midha, Omar Nadeem, Melissa Alsina, Rachid Baz, Kenneth Shain, Frederick Locke, Shaji Kumar, Krina Patel, Surbhi Sidana, Doris Hansen

Blood (2025) 146 (Supplement 1): 4000.

https://doi.org/10.1182/blood-2025-4000

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open‑label Phase 2 ALPHA3 study

Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations

Major adverse cardiovascular events after teclistamab in relapsed refractory multiple myeloma: A multicenter study from the u.s. multiple myeloma immunotherapy consortium.

Real-world outcomes of talquetamab in Relapsed/Refractory multiple myeloma

Real-world efficacy outcomes of epcoritamab and glofitamab in Relapsed/Refractory aggressive B-cell lymphoma: A single-center cohort emphasizing trial-ineligible populations

Real-world outcomes with elranatamab in multiple myeloma: A multi-center analysis from the United States multiple myeloma immunotherapy consortium

Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium

Real-time multimodal AI outperforms conventional scores for early risk prediction in BCMA CAR-T–Treated myeloma

CD83 CAR T overcome CD19 antigen loss in B cell malignancies after CD19-directed therapy

Impact of pre-existing psychiatric conditions on toxicity and outcomes of patients after BCMA-directed CAR-T cell therapy

Developing SEMA4A-directed CAR t cells to overcome low BCMA antigen density in multiple myeloma

Impact of pre-existing central nervous system conditions and cognitive impairments on toxicity and outcomes after BCMA-directed CAR-T cell therapy

Impact of autoimmune disease on outcomes after BCMA-directed CAR-T cell therapy for patients with multiple myeloma

Real-world outcomes of immune effector cell-associated hemophagocytic syndrome (IEC-HS) following ide-cel and cilta-cel therapy in relapsed/refractory multiple myeloma

Optimal ferritin threshold to diagnose immune effector cell-associated hemophagocytic syndrome (IEC-HS) following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM)

Optimizing immunity to pneumococcus by vaccination with pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T cell immunotherapy

Real-world effectiveness and safety outcomes by age, comorbidities, and frailty among relapsed or refractory (R/R) Mantle Cell Lymphoma (MCL) patients treated with brexucabtagene autoleucel (brexu-cel)

Outcomes of CD20xCD3 bispecific antibody therapy as holding or bridging therapy prior to chimeric antigen receptor T-cell infusion in aggressive B-cell lymphomas

Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study

Identifying candidates for outpatient administration of ciltacabtagene autoleucel (Cilta-cel) in relapsed-refractory multiple myeloma (RRMM)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only